Although the healthcare sector has lately been hit by the news that Johnson and Johnson (
JNJ Quick Quote JNJ - Free Report) and Eli Lilly ( LLY Quick Quote LLY - Free Report) have halted their trials for the novel disease vaccine over safety concerns, it is expected to witness the second-highest earnings growth this earnings season. The ultra-popular ETFs, Health Care Select Sector SPDR Fund (, XLV Quick Quote XLV - Free Report) Vanguard Health Care ETF (, VHT Quick Quote VHT - Free Report) iShares U.S. Healthcare ETF ( and IYH Quick Quote IYH - Free Report) Fidelity MSCI Health Care Index ETF (, have gained around 1% in the past three months (read: FHLC Quick Quote FHLC - Free Report) JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus). The price movement of the fund depends on earnings releases of some big names like Pfizer ( PFE Quick Quote PFE - Free Report) , Merck ( MRK Quick Quote MRK - Free Report) , Amgen ( AMGN Quick Quote AMGN - Free Report) , AbbVie ( ABBV Quick Quote ABBV - Free Report) , Gilead Sciences ( GILD Quick Quote GILD - Free Report) and Bristol-Myers Squibb ( BMY Quick Quote BMY - Free Report) that dominate returns. These firms are lined up to report their earnings in the coming weeks. All these stocks collectively account for 22.6% share in XLV, 20.4% in IYH, 19.6% in VHT and 19.4% in FHLC. Let’s dig deeper into the earnings picture of these companies, which will drive the performance of the above-mentioned funds in the coming days: According to our methodology, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Inside Our Surprise Prediction for These Stocks
Pfizer has a Zacks Rank #3 and an Earnings ESP of -0.12%. The stock witnessed negative earnings estimate revision of a couple of cents for the to-be-reported quarter over the past 30 days. It delivered earnings surprise of 12.53%, on average, in the past four quarters and has a Value Score of B. Pfizer is scheduled to report earnings on Oct 27, before the opening bell.
Merck is expected to report results on Oct 27 before market open. It has a Zacks Rank #3 and an Earnings ESP of +2.60%. The stock witnessed negative earnings estimate revision of a penny over the past 30 days for the to-be-reported quarter. Additionally, the stock delivered an average beat of 12.66% in the last four quarters. Merck has a VGM Score of A (see: all the Healthcare ETFs here). Amgen carries a Zacks Rank #3 and has an Earnings ESP of +0.01%. It has witnessed positive earnings estimate revision of a penny over the past 30 days for the quarter to be reported. Analysts raising estimates right before earnings — with the most up-to-date information possible — is a good indicator for the stock. The earnings surprise track over the past four quarters is strong, with the beat being 8.58%, on average. The stock has a VGM Score of A. Amgen will report earnings on Oct 28. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.97%. The company delivered earnings surprise of 3.32%, on average, in the last four quarters. It saw negative earnings estimate revision of a penny over the past month for the to-be-reported quarter. The stock has a top Value Score of A. The company is scheduled to report on Oct 30 before the opening bell. Gilead is expected to release earnings on Oct 28 after market close. It has a Zacks Rank #3 and an Earnings ESP of 0.00%. The stock saw negative earnings estimate revision of 3 cents over the past month for the to-be-reported quarter. Gilead’s negative earnings surprise was 10.21%, on average, over the last four quarters. Gilead has a VGM Score of A. Bristol-Myers will likely report earnings on Nov 5 before the opening bell. It has a Zacks Rank #3 and an Earnings ESP of +1.01%. The stock delivered an earnings surprise of 8.02%, on average, over the past four quarters, but saw negative earnings estimate revision of a penny for the to-be-reported quarter in a month. It has a VGM Score of A (read: Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal). Summing Up
The healthcare sector is expected to witness substantial earnings growth of
5.1% in the third quarter, representing the second strongest sector this earnings season. In particular, FHLC has a Zacks ETF Rank #3 while the remaining three have a Zacks ETF Rank #2. Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>